AKHAVAN ARDAVAN ET AL: "Endothelin receptor a blockade enhances taxane effects in prostate cancer", NEOPLASIA (NEW YORK), vol. 8, no. 9, September 2006 (2006-09), pages 725-732, XP002605978, ISSN: 1522-8002 (B1)

BAGNATO A ET AL: "The endothelin axis in cancer", INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY, EXETER, GB LNKD- DOI:10.1016/J.BIOCEL.2008.01.022, vol. 40, no. 8, 1 January 2008 (2008-01-01), pages 1443-1451, XP022655988, ISSN: 1357-2725 [retrieved on 2008-02-01] (B1)

WO-A1-2004/035057 (B1)

PHUPHANICH SURASAK ET AL: "Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma.", NEURO-ONCOLOGY AUG 2008 LNKD- PUBMED:18477765, vol. 10, no. 4, August 2008 (2008-08), pages 617-623, XP002605977, ISSN: 1522-8517 (B1)

RICHARD KEFFORD ET AL: "A Phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma", INVESTIGATIONAL NEW DRUGS ; THE JOURNAL OF NEW ANTICANCER AGENTS, KLUWER ACADEMIC PUBLISHERS, BO, vol. 25, no. 3, 5 October 2006 (2006-10-05), pages 247-252, XP019500025, ISSN: 1573-0646 (B1)

CHIAPPORI ALBERTO A ET AL: "Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 1 MAR 2008 LNKD- PUBMED:18316570, vol. 14, no. 5, 1 March 2008 (2008-03-01), pages 1464-1469, XP002605976, ISSN: 1078-0432 (B1)